Antihistamines, Respiratory Viruses and Thrombosis While an increasing trend in thrombotic events was observed across all polypharmacy subgroups and centers in the non–AntiHm group (ranging from patients with no prior chronic conditions to those receiving ≥8 chronic treatments [nT]), a highly significant reduction was observed among AntiH-treated patients in most polypharmacy subgroups, suggesting a potential protective role, as previously reported for H1 antihistamines with respect to hospital admissions and mortality [ 14 , 16 , 17 ].
← all excerpts
Long COVID and Reduced Thrombosis in Antihistamine-Treated Patients: An Observational Study in the Metropolitan Area of Barcelona.
1
—
—